PT  - JOURNAL ARTICLE
AU  - The OpenSAFELY Collaborative
AU  - Elizabeth Williamson
AU  - Alex J Walker
AU  - Krishnan Bhaskaran
AU  - Seb Bacon
AU  - Chris Bates
AU  - Caroline E Morton
AU  - Helen J Curtis
AU  - Amir Mehrkar
AU  - David Evans
AU  - Peter Inglesby
AU  - Jonathan Cockburn
AU  - Helen I McDonald
AU  - Brian MacKenna
AU  - Laurie Tomlinson
AU  - Ian J Douglas
AU  - Christopher T Rentsch
AU  - Rohini Mathur
AU  - Angel Wong
AU  - Richard Grieve
AU  - David Harrison
AU  - Harriet Forbes
AU  - Anna Schultze
AU  - Richard Croker
AU  - John Parry
AU  - Frank Hester
AU  - Sam Harper
AU  - Raf Perera
AU  - Stephen Evans
AU  - Liam Smeeth
AU  - Ben Goldacre
TI  - OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients
AID  - 10.1101/2020.05.06.20092999
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.06.20092999
4099  - http://medrxiv.org/content/early/2020/05/07/2020.05.06.20092999.short
4100  - http://medrxiv.org/content/early/2020/05/07/2020.05.06.20092999.full
AB  - Background Establishing who is at risk from a novel rapidly arising cause of death, and why, requires a new approach to epidemiological research with very large datasets and timely data. Working on behalf of NHS England we therefore set out to deliver a secure and pseudonymised analytics platform inside the data centre of a major primary care electronic health records vendor establishing coverage across detailed primary care records for a substantial proportion of all patients in England. The following results are preliminary.Data sources Primary care electronic health records managed by the electronic health record vendor TPP, pseudonymously linked to patient-level data from the COVID-19 Patient Notification System (CPNS) for death of hospital inpatients with confirmed COVID-19, using the new OpenSAFELY platform.Population 17,425,445 adults.Time period 1st Feb 2020 to 25th April 2020.Primary outcome Death in hospital among people with confirmed COVID-19.Methods Cohort study analysed by Cox-regression to generate hazard ratios: age and sex adjusted, and multiply adjusted for co-variates selected prospectively on the basis of clinical interest and prior findings.Results There were 5683 deaths attributed to COVID-19. In summary after full adjustment, death from COVID-19 was strongly associated with: being male (hazard ratio 1.99, 95%CI 1.88-2.10); older age and deprivation (both with a strong gradient); uncontrolled diabetes (HR 2.36 95% CI 2.18-2.56); severe asthma (HR 1.25 CI 1.08-1.44); and various other prior medical conditions. Compared to people with ethnicity recorded as white, black people were at higher risk of death, with only partial attenuation in hazard ratios from the fully adjusted model (age-sex adjusted HR 2.17 95% CI 1.84-2.57; fully adjusted HR 1.71 95% CI 1.44-2.02); with similar findings for Asian people (age-sex adjusted HR 1.95 95% CI 1.73-2.18; fully adjusted HR 1.62 95% CI 1.431.82).Conclusions We have quantified a range of clinical risk factors for death from COVID-19, some of which were not previously well characterised, in the largest cohort study conducted by any country to date. People from Asian and black groups are at markedly increased risk of in-hospital death from COVID-19, and contrary to some prior speculation this is only partially attributable to pre-existing clinical risk factors or deprivation; further research into the drivers of this association is therefore urgently required. Deprivation is also a major risk factor with, again, little of the excess risk explained by co-morbidity or other risk factors. The findings for clinical risk factors are concordant with policies in the UK for protecting those at highest risk. Our OpenSAFELY platform is rapidly adding further NHS patients’ records; we will update and extend these results regularly.Competing Interest StatementCB JP FH JC SH are employees of TPP.Funding StatementNo dedicated funding has yet been obtained for this work. TPP provided technical expertise and infrastructure within their data centre pro bono in the context of a national emergency. BG's work on better use of data in healthcare more broadly is currently funded in part by: NIHR Oxford Biomedical Research Centre, NIHR Applied Research Collaboration Oxford and Thames Valley, the Mohn-Westlake Foundation, NHS England, and the Health Foundation; all DataLab staff are supported by BG's grants on this work. LS reports grants from Wellcome, MRC, NIHR, UKRI, British Council, GSK, British Heart Foundation, and Diabetes UK outside this work. KB holds a Sir Henry Dale fellowship jointly funded by Wellcome and the Royal Society. HIM is funded by the National Institute for Health Research (NIHR) Health Protection Research Unit in Immunisation, a partnership between Public Health England and LSHTM. AW holds a fellowship from BHF. RM holds a Sir Henry Wellcome fellowship. EW holds grants from MRC. RG holds grants from NIHR and MRC. ID golds grants from NIHR and GSK. RM holds a Sir Henry Wellcome Fellowship funded by the Wellcome Trust. HF holds a UKRI fellowship. The views expressed are those of the authors and not necessarily those of the NIHR, NHS England, Public Health England or the Department of Health and Social Care. Funders had no role in the study design, collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll code for data management and analysis is archived online at https://github.com/ebmdatalab/opensafely-risk-factors-research. All clinical and medicines codelists are openly available for inspection and reuse at https://codelists.opensafely.org/. https://github.com/ebmdatalab/opensafely-risk-factors-research https://codelists.opensafely.org/